Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine

Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine.

Human vaccination with BioThrax requires six injections followed by annual boosters. This makes it difficult for the compliance of the immunization program and underscores the need for development of a new and optimized vaccination protocol. Current research aims to demonstrate the proof of concept to develop a needle-free mucosal immunization protocol using a murine anthrax model. A/J mice wer...

Detoxified lethal toxin as a potential mucosal vaccine against anthrax.

The nontoxic mutant lethal factor (mLF; which has the E687C substitution) and functional protective antigen (PA63) of Bacillus anthracis were evaluated for their use as mucosal vaccines against anthrax in A/J mice. Intranasal vaccination of three doses of 30 microg of mLF or 60 microg of PA63 elicited significant serum and mucosal antibody responses, with anthrax lethal toxin-neutralizing titer...

A new Approach to active Immunization of Sheep by a combined Sheep pox and Anthrax Vaccine

Immunization of Cattle and Buffaloes With a Combined Anthrax, Haemorrhagic septicaemia and Blackleg Vaccine in Iran

Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.

The currently available commercial human anthrax vaccine requires multiple injections for efficacy and has side effects due to its alum adjuvant. These factors limit its utility when immunizing exposed populations in emergent situations. We evaluated a novel mucosal adjuvant that consists of a nontoxic, water-in-oil nanoemulsion (NE). This material does not contain a proinflammatory component b...